The ketogenic diet's rise to mainstream popularity created an entire supplement subcategory: exogenous ketone products, MCT oils, electrolyte formulas for keto adherents, and products marketed to support fat burning and ketosis. None of these claim types have special regulatory pathways. They all operate under the general DSHEA structure/function framework — and several of the most common keto claims are either substantiation problems or outright disease claims.
What "Keto-Friendly" Actually Means Legally
"Keto-friendly" has no FDA definition. It functions as an implied nutrient content claim — similar to "low carb" — indicating the product is low in carbohydrates and suitable for someone following a ketogenic diet. Like other implied claims, it must be truthful and not misleading under 21 CFR 101.65(d)(2).
The practical standard: a product marketed as "keto-friendly" should have a carbohydrate content consistent with keto dietary guidelines (typically very low net carbs). A product with significant carbohydrate content from sugar alcohols, fibers, or other sources that are not fully excluded from net carb calculations creates a truthfulness and substantiation issue when marketed as "keto."
Structure/Function Claims for Keto Supplements
Under 21 CFR 101.93(f), permissible structure/function claims in the keto category include:
"Supports healthy fat metabolism"
"Promotes ketone production"
"Supports healthy energy metabolism on a low-carb diet"
"Promotes healthy electrolyte balance"
"Supports mental clarity and focus"
"Promotes healthy mitochondrial energy production"
"Supports the body's use of fat for energy"
These describe normal metabolic functions. They don't imply treatment of metabolic disease or obesity.
Where Keto Claims Cross the Line
Prohibited disease claims:
"Treats obesity" — obesity is a named disease; treatment claims require drug approval
"For people with type 2 diabetes" — targeting a disease population; ketogenic diets are used medically for diabetes management, so positioning a supplement as part of that management is a disease claim
"Manages insulin resistance" — insulin resistance is a clinical condition
"Treats epilepsy" — ketogenic diets are used clinically for epilepsy; a supplement claiming to "support ketosis for seizure management" is making a disease claim
"Reduces cancer risk through ketosis" — disease prevention claim
"Supports cancer treatment" — adjunctive disease treatment claim
The epilepsy connection is particularly important: the ketogenic diet has an FDA-recognized role in managing drug-resistant epilepsy. Any supplement that references "ketosis for seizure reduction" or "neurological ketosis" is making a disease claim for a named condition (epilepsy) under 21 CFR 101.93(g).
Exogenous Ketones: BHB Salts and Esters
Beta-hydroxybutyrate (BHB) salts are the primary exogenous ketone ingredient. Structure/function claims about BHB supporting ketone levels, energy metabolism, and mental clarity may be potentially permissible. Claims about BHB "putting you in ketosis" as a therapeutic intervention for disease management, or claims about specific clinical outcomes at medical-grade doses, are higher-risk.
BHB esters — more potent than BHB salts — may also face NDI notification requirements depending on the specific form and whether a pre-1994 market history can be established for that form.
"Burns Fat" and Weight Loss Claims
"Supports fat burning" and similar claims in the keto context carry the same risks as any weight loss claim under 21 CFR 101.93(g). These claims imply treatment of obesity or are implied weight loss claims subject to the full weight management claim analysis. "Supports healthy fat metabolism" is the lower-risk framing.
MCT Oil Claims
Medium-chain triglycerides (MCT oil) have a well-established market history as a dietary supplement ingredient. Structure/function claims about MCT supporting healthy energy metabolism, promoting ketone production on a low-carb diet, and supporting healthy cognitive function are potentially permissible with appropriate substantiation. Claims about MCT treating Alzheimer's or cognitive decline are disease claims.
Keto supplement compliance requires applying the standard structure/function framework to a category with no special rules
Truli reviews keto supplement claims against 21 CFR 101.93 — flagging "keto-friendly" substantiation issues, disease claims tied to metabolic conditions and epilepsy, and weight management language that crosses from structure/function support into prohibited disease treatment territory.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
